Robert Hayes

Biography

Robert Hayes is the former Head of Biologics at Amgen and Vice President at Janssen Pharmaceuticals, a Johnson and Johnson company, where he was the Head of Centyrex, a biotechnology company dedicated towards developing novel proteins as therapeutics with transformational properties. During this time, Centyrex entered into a collaboration with Phylogica to understand the ability to use Phylomers to deliver therapeutic proteins into cells. Rob brings over 18 years of experience in biotechnology research and development to Phylogica. In this newly created role, he will lead all aspects of discovery research at Phylogica. At Amgen, he was responsible for leadership, operational and strategic management of all aspects of biologics preclinical discovery and the biotherapeutics pipeline, including bioreagent generation, large molecule identification, optimization and transition to the manufacturing arm. At Centyrex, Rob established programs resulting in multiple strategic alliances with partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in both oncology and immunology. Before that, Rob was Director of Antibody Engineering at Xencor, an antibody and protein engineering and development company.

Research Interest

  Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management